VivaVision has submitted a listing application to the Hong Kong Stock Exchange (HKEX). Founded in 2016, the clinical-stage biotech company focuses on developing first-in-class and best-in-class therapies for ocular diseases, including conditions of the ocular surface and retina. The company has raised a cumulative total of RMB 735 million (USD 106 million) through multiple funding rounds, with its most recent post-money valuation at approximately RMB 1.8 billion.

VivaVision's pipeline includes two core assets: VVN461, a JAK1/TYK2 inhibitor in Phase III trials for non-infectious anterior uveitis, and VVN001, a second-generation LFA-1 antagonist in Phase III development for dry eye disease. The company also has other candidates for glaucoma and retinal diseases. Proceeds from the IPO will be used to advance the clinical development and potential commercialisation of its lead products, expand its R&D pipeline and for general corporate purposes. The company reported a net loss of RMB 131.5 million for the first nine months of 2025.

PharmCube's NextBiopharm® database shows that VivaVision subsidiary E-nitiate Bio previously licensed PDE4 inhibitor QY101 to Chinese compatriot Joincare Pharma. Click here to request a free trial for NextBiopharm®.